Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.37 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002674 | 0.91 | GRM2 (0.51) | GRM2MAOAMAOBCHRM4CHRM2 | |
| SCHEMBL12413538 | 0.91 | GRM2 (0.47) | GRM2MAOAMAOBALDH1A1TSHR | |
| SCHEMBL1002787 | 0.89 | CCR3 (0.41) | MAOAMAOBALDH1A1HRH1CCR3 | |
| SCHEMBL2020644 | 0.88 | GRM2 (0.44) | GRM2CHRM4CHRM2CHRM1ALDH1A1 | |
| SCHEMBL1002971 | 0.88 | MAOA (0.40) | MAOAMAOBCHRM4ALDH1A1TSHR | |
| SCHEMBL1001901 | 0.88 | ALDH1A1 (0.45) | MAOAMAOBALDH1A1HRH1CCR3 | |
| SCHEMBL2027732 | 0.86 | ALDH1A1 (0.45) | GRM2CHRM4ALDH1A1TSHRCCR2 | |
| SCHEMBL1002428 | 0.84 | PARP1 (0.44) | MAOAMAOBCHRM4ALDH1A1HRH1 | |
| SCHEMBL1003992 | 0.84 | GRM2 (0.47) | GRM2ALDH1A1 | |
| SCHEMBL2024727 | 0.82 | GRM2 (0.44) | GRM2ALDH1A1TSHRCYP3A4GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101039907-B | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB | 2011-02-23 | — | — | CN | claimed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | claimed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | claimed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| CN-101309905-A | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2008-11-19 | — | — | CN | claimed |
| EP-1912940-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | claimed |
| CN-101039907-A | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | CN | claimed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | claimed |
| WO-2007021309-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | claimed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | claimed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| CN-102134214-A | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA SWEDEN AB | 2011-07-27 | — | — | CN | disclosed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| EP-1912940-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| CN-101039907-A | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007021309-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | GRM2 3/4885MAOA 3306/4885MAOB 2952/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885MAOA 4014/4885MAOB 3508/4885 |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885MAOA 3306/4885MAOB 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.